ONMA Stock Overview
OncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
OncoSec Medical Incorporated Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.085 |
| 52 Week High | US$17.82 |
| 52 Week Low | US$0.085 |
| Beta | 2 |
| 1 Month Change | -79.22% |
| 3 Month Change | -95.82% |
| 1 Year Change | -99.49% |
| 3 Year Change | -99.78% |
| 5 Year Change | -99.97% |
| Change since IPO | -99.99% |
Recent News & Updates
Recent updates
Shareholder Returns
| ONMA | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -46.3% | -5.1% | -2.0% |
| 1Y | -99.5% | -21.1% | -0.3% |
Return vs Industry: ONMA underperformed the German Biotechs industry which returned -23.1% over the past year.
Return vs Market: ONMA underperformed the German Market which returned 5.9% over the past year.
Price Volatility
| ONMA volatility | |
|---|---|
| ONMA Average Weekly Movement | 44.4% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: ONMA's share price has been volatile over the past 3 months.
Volatility Over Time: ONMA's weekly volatility has decreased from 220% to 44% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 41 | n/a | oncosec.com |
OncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. The company’s product pipeline includes KEYNOTE-695, which is in Phase 2 trial for the treatment of advanced melanoma; TAVO + SARS-CoV-2 spike glycoprotein, which is in Phase 1 clinical trial for the treatment of COVID-19; and TAVO + epacadostat + pembrolizumab, which is in Phase 1 clinical trial for the treatment of squamous cell carcinoma head and neck cancer. Its pipeline also comprises TAVO +nivolumab, which is in Phase 2 clinical trial for the treatment of breast cancer; TAVO + CXCL9 for the treatment of solid tumors; and OMS-100 and OMS-102, which are in Phase 2 clinical trial for the treatment of metastatic melanoma.
OncoSec Medical Incorporated Fundamentals Summary
| ONMA fundamental statistics | |
|---|---|
| Market cap | €737.99k |
| Earnings (TTM) | -€26.94m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs ONMA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ONMA income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$29.39m |
| Earnings | -US$29.39m |
Last Reported Earnings
Jan 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.93 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -132.9% |
How did ONMA perform over the long term?
See historical performance and comparison